Vulnerable Covid patients treated with Paxlovid find symptoms improve ‘within hours'
THE CORONAVIRUS pandemic has been ongoing for more than two
years. Recently restrictions were lifted allowing many to enjoy places they
hadn't done so for years. However, for some vulnerable patients, the ongoing
anxiety around Covid continues.
08:51, Mon, Apr 11, 2022 |
UPDATED: 08:51, Mon, Apr 11, 2022
https://www.express.co.uk/life-style/health/1594196/coronavirus-treatment-paxlovid-improve-symptoms
In April 2020, the UK was in the middle of its first national lockdown. Nowhere was open apart from supermarkets and pharmacies. Today the picture is much different, and every form of shop, bar, and entertainment venue is open to the public. However, people are still getting Covid and still requiring treatment as a result. To help some of those patients the government has procured millions of doses of antiviral drugs to help treat people at home.
One of the drugs in question is known as
Paxlovid.
In trials Paxlovid was found to cut COVID-19 hospital
admissions and deaths by 88 percent.
So far the antiviral treatment has been given
to more than 6000 patients with the most recent 1400 in the past week.
Like some other antivirals, Paxlovid has been
found to relieve symptoms “within hours” of administration.
It isn’t the only drug the UK has procured.
So too has Molnupiravir.
Although not as effective as Paxlovid, studies
have nevertheless found the drug can reduce the risk of admission to hospital
or death by 30 percent.
The drug was approved in November 2021 and has
been used as an at-home treatment for the past five months.
I love reading about the drugs that are used to treat Covid symptoms, thank you for the share, Gary! I think antivirals are saviors in this stage of the pandemic because it feels as if life is continuing regardless of Covid diagnoses. I do wonder if this will lead us into a world with viral resistance as we've seen with antibacterial medications? Evolution will catch up to us eventually, and I don't think any drug company sees much money coming from the production/research of antivirals beyond this pandemic; there will be little incentive to continue this important research.
ReplyDelete